SCHEMBL17818397

SCHEMBL17818397

Nc1ncnc2c1c(I)cn2C1CCCCC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 7/20 0.63
LCK P06239 4/20 0.63
RET P07949 3/20 0.63
KDR P35968 3/20 0.63
CSF1R P07333 2/20 0.63
IGF1R P08069 2/20 0.63
FGFR1 P11362 2/20 0.63
FLT1 P17948 2/20 0.63
FLT3 P36888 2/20 0.63
MST1R Q04912 2/20 0.63
NTRK3 Q16288 2/20 0.63
NTRK2 Q16620 2/20 0.63
ALK Q9UM73 2/20 0.63
FYN P06241 2/20 0.63
DAPK3 O43293 1/20 0.63
MAP4K4 O95819 1/20 0.63
PAK4 O96013 1/20 0.63
PRKACA P17612 1/20 0.63
LTK P29376 1/20 0.63
MAP2K2 P36507 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1940882 0.98 ABL1 (0.64) ABL1LCKRETKDRCSF1R
SCHEMBL30155310 0.98 ABL1 (0.64) ABL1LCKRETKDRCSF1R
SCHEMBL29484468 0.95 SRC (0.61) ABL1LCKRETKDRCSF1R
SCHEMBL400626 0.95 SRC (0.61) ABL1LCKRETKDRCSF1R
SCHEMBL16237288 0.92 SRC (0.59) ABL1LCKRETKDRCSF1R
SCHEMBL1933264 0.87 RIPK2 (0.63) ABL1LCKRETKDRCSF1R
SCHEMBL1933267 0.87 RIPK2 (0.63) ABL1LCKRETKDRCSF1R
SCHEMBL9950847 0.86 ADK (0.62) ABL1LCKRETKDRCSF1R
SCHEMBL9950846 0.86 ADK (0.62) ABL1LCKRETKDRCSF1R
SCHEMBL19743649 0.86 FGR (0.57) ABL1LCKRETKDRCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2997030-B1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2017-08-09 EP disclosed
US-9682083-B2 Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2017-06-20 US disclosed
US-20160166575-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-06-16 US disclosed
CN-105431436-A Pyrrolo [2,3-D ] pyrimidine derivatives, processes for their preparation and their use as kinase inhibitors NERVIANO MEDICAL SCIENCES SRL 2016-03-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166575-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS RET, DCK, PRKD2 ABL1 159/4885LCK 121/4885RET 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.